Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

1. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 EvidenceUpdates

2. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

3. Methylphenidate (Ritalin) as a means of controlling classroom behaviour

Methylphenidate (Ritalin) as a means of controlling classroom behaviour Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin°) as a means of controlling classroom behaviour'', 1 May 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Too many children are overdiagnosed with attention deficit hyperactivity disorder (ADHD) simply because they are the youngest in the class and so tend to be more easily distracted and disruptive. Children are diagnosed with attention deficit with or without hyperactivity when they exhibit various non-specific symptoms such as difficulty concentrating in class, fidgetiness and impulsivity. The boundaries are unclear. At best

2019 Prescrire

4. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. (PubMed)

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

5. Methylphenidate remains first-choice drug treatment for children and young people with ADHD

Methylphenidate remains first-choice drug treatment for children and young people with ADHD Methylphenidate remains first-choice drug treatment for children and young people with ADHD Discover Portal Discover Portal Methylphenidate remains first-choice drug treatment for children and young people with ADHD Published on 6 November 2018 doi: The stimulant methylphenidate has the best balance of effectiveness against side effects in children and young people with attention deficit hyperactivity (...) or development. It is thought to affect around 5% of children worldwide and is more common in boys than girls. Many children improve with behavioural interventions and family support, with drug treatments reserved for more those more severely affected. Drug treatments include stimulants (such as methylphenidate and amphetamines) and non-stimulants (such as atomoxetine). This review aimed to compare the available drugs using a network meta-analysis. This type of analysis can weigh up the effectiveness

2019 NIHR Dissemination Centre

6. Efficacy of Methylphenidate in the Geriatric Population for Fall Prevention

Efficacy of Methylphenidate in the Geriatric Population for Fall Prevention "Efficacy of Methylphenidate in the Geriatric Population for Fall Preve" by Adam Stapleton < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract || Abstract || Background: Approximately one-third of people aged 65 years and over who are not living in institutions fall at least once a year, with higher rates (...) among those living in institutions. One half of older adults who are hospitalized as a result of a fall survive one year later.The importance of fall prevention in older adults is well researched, with many established community based programs in the United States focusing on exercise and fundamental education for fall reduction. However, new options for prevention are being explored. Executive function and gait, both related to falls, may be improved by methylphenidate, providing a promising option

2018 Pacific University EBM Capstone Project

7. Methylphenidate

Methylphenidate Top results for methylphenidate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for methylphenidate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

8. Prevalence of nonmedical use of prescription-type opioids, methylphenidate, and sedative-hypnotics among university students in the south of Iran: a regression analysis (PubMed)

Prevalence of nonmedical use of prescription-type opioids, methylphenidate, and sedative-hypnotics among university students in the south of Iran: a regression analysis Nonmedical use of prescription drugs needs particular attention. The aim of this study was to determine the prevalence of prescription-type opioids, methylphenidate and sedative-hypnotics use, and related factors in university students.In this cross-sectional study, 524 students of Hormozgan University of Medical Sciences were (...) was performed using Chi-square test, Fisher exact test, independent-samples t-test and binary logistic regression in SPSS 16 software. The level of significance was 0.05.The last year prevalence of prescription-type opioids, methylphenidate and sedative-hypnotics use was 16.1%, 3.3%, and 10.3%, respectively. The final model of logistic regression indicated hookah use (OR=2.5), methylphenidate use (OR=4.5), sedative-hypnotics use (OR=2.7), and were associated with students' prescription-type opioids use

Full Text available with Trip Pro

2018 Electronic physician

9. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. (PubMed)

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies.In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases

Full Text available with Trip Pro

2018 Cochrane

10. Efficacy of methylphenidate in adults with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis

Efficacy of methylphenidate in adults with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

11. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol]

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

12. Efficacy and tolerability of methylphenidate and atomoxetine in the treatment of core symptoms of Attention Deficit Hyperkinetic Disorder (ADHD) in children and young people (CYP) with co-occurring ADHD and Autism Spectrum Disorder (ASD): a systematic rev

Efficacy and tolerability of methylphenidate and atomoxetine in the treatment of core symptoms of Attention Deficit Hyperkinetic Disorder (ADHD) in children and young people (CYP) with co-occurring ADHD and Autism Spectrum Disorder (ASD): a systematic rev Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2018 PROSPERO

13. Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review

Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

14. Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis

Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

15. Clinical and pharmacological properties of methylphenidate: a systematic review

Clinical and pharmacological properties of methylphenidate: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

16. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial Apathy is a common behavioral problem in Alzheimer's disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease.A 12-week, prospective, double-blind (...) , randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary outcomes for cognition (Mini-Mental State Examination, Modified Mini-Mental State Examination), functional status (activities of daily living, instrumental activities of daily living), improvement and severity (Clinical Global Impressions Scale [CGI]), caregiver burden

Full Text available with Trip Pro

2017 EvidenceUpdates

17. Methylphenidate for children and adolescents with autism spectrum disorder. (PubMed)

Methylphenidate for children and adolescents with autism spectrum disorder. Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention deficit hyperactivity disorder (ADHD). The effectiveness of methylphenidate, a commonly used ADHD treatment, is therefore of interest in these children.To assess the effects of methylphenidate for symptoms of ADHD (inattention, impulsivity and hyperactivity (...) ) and ASD (impairments in social interaction and communication, and repetitive, restricted or stereotypical behaviours) in children and adolescents aged 6 to 18 years with ASD.In November 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 11 other databases and two trials registers. We also checked reference lists and contacted study authors and pharmaceutical companies.Randomised controlled trials (RCTs) that investigated the effect of methylphenidate versus placebo on the core symptoms

Full Text available with Trip Pro

2017 Cochrane

18. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists (PubMed)

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects children, adolescents, and adults worldwide. The purpose of this review was to inform pharmacists of the numerous options to treat ADHD, with a focus on one of the more recently approved formulations, methylphenidate extended-release oral suspension (MEROS (...) ). Symptoms of ADHD can negatively impact an individual's health and quality of life and impair function in multiple settings. Psychostimulants such as methylphenidate- and amphetamine-based agents are first-line pharmacologic treatments for ADHD. However, there are multiple formulations, including immediate release (administered two to three times/day), solid extended release (ER), or transdermal patch. MEROS is a once daily, long-acting liquid preparation that has demonstrated favorable safety

Full Text available with Trip Pro

2017 Integrated pharmacy research & practice

19. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial (PubMed)

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

Full Text available with Trip Pro

2017 Electronic physician Controlled trial quality: uncertain

20. Methylphenidate and the elderly

Methylphenidate and the elderly Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email

2017 PROSPERO